News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|April 12, 2021

Debunking 4 Myths Around Mass Shootings

Author(s)Tony Thrasher, DO, MBA, CPE, DFAPA

As the recent waves of violence show, a conversation needs to be had on mass shootings and gun violence...

Tony Thrasher, DO, DFAPA, talks about 4 crucial misunderstandings about mass shootings.

Dr Thrasher is the president of the American Association for Emergency Psychiatry (AAEP) and the medical director of crisis services in Milwaukee county, Wisconsin.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

1 expert is featured in this series.

The Switch Study: Why a New Mechanism Demands a New Approach

ByDavid Walling, PhD

June 17th 2026

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

ByJames Rachal, MD

May 16th 2026

PTSD

Multilayered Trauma, One PTSD Diagnosis?

ByErica Browne,Catalina Belean, MD

March 9th 2026

child victim

Mandatory Reporting: Child Sexual Exploitation Material

ByAriana Gilani, MD,Renee Sorrentino, MD

February 27th 2026

psychedelic

Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD

ByKeith Jenkins, DNP, PMHNP-BC, FNP-C, AGNP-C

February 20th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Psychiatric Pharmacogenomics: An Overview

Evaluating Transdermal Asenapine in Schizophrenia

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint